07:10 AM EDT, 10/20/2025 (MT Newswires) -- Grail (GRAL) and the University of Oxford said Monday that data from its SYMPLIFY multi-cancer early detection study showed that 35.4% of participants initially believed to have a false-positive result were later diagnosed with cancer during follow-up.

The SYMPLIFY observational study evaluated individuals who presented with symptoms to primary care and were referred for diagnostic follow-up for suspicion of cancer, they said.

The study, which used the Galleri test to assess blood samples from over 6,000 participants with symptoms of cancer, showed that 28 out of 79 participants with initial false-positive reports were later diagnosed with cancer within 24 months of enrollment, according to the statement.

Long-term results from an extended registry follow-up of the study will be presented on Tuesday at the Early Detection of Cancer Conference in Portland, they said.

Shares of the company were up nearly 13% in recent Monday premarket activity.